Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Helicobacter pylori eradication significantly reduces the relapse rate of ulcer-like dyspepsia

Helicobacter pylori eradication results in a significant reduction in symptomatic relapse in patients presenting with ulcer-like dyspepsia in primary care, the BSG conference has been told.

News image

fiogf49gjkf04

A team from Oxford and Taplow, England, investigated the role of H. pylori eradication in the treatment of ulcer-like dyspepsia in primary care.

Their findings were reported to the British Society of Gastroenterology Annual Conference, held this week in Glasgow, Scotland.

543 patients from 64 primary care centers in the UK and Norway were enrolled into the study. Individuals with confirmed ulcer were excluded from the investigation.

364 patients were assessed as H. pylori-positive by near patient antibody blood test.

Of these, 181 patients were randomized to receive eradication therapy (lansoprazole 30 mg, clarithromycin 250 mg and amoxycillin 1g, all twice a day) for 1 week, followed by lansoprazole 30 mg once a day for 3 or 7 weeks, according to symptoms.

Ulcer-like dyspepsia relapse rate:
Eradication therapy group 37%
Lansoprazole only, H. pylori-positive 51%
Lansoprazole only, H. pylori-negative 59%
British Society of Gastroenterology Annual Meeting

183 subjects received placebo antibiotics and lansoprazole 30 mg once a day for 4 or 8 weeks.

179 H. pylori-negative patients received open treatment with lansoprazole 30 mg once a day for 4 or 8 weeks.

Epigastric pain, and other gastrointestinal symptoms, consultations, prescriptions, and investigations were recorded during the treatment period and over a 12-month follow-up phase.

The researchers found the relapse rate of ulcer-like dyspepsia during the follow-up period, to be 37% in subjects who underwent eradication therapy. In subjects receiving just lansoprazole, relapse rates were 51% and 59% for H. pylori-positive and negative individuals, respectively.

The average number of GI consultations and prescriptions was lower in the eradication group compared with the H. pylori-positive, non-eradicated group.

Richard Stevens, of the East Oxford Health Centre, concluded on behalf of the group, "H. pylori eradication resulted in a significant reduction in symptomatic relapse in patients presenting with ulcer-like dyspepsia in primary care.

"This was associated with a reduction in the number of GI consultations and prescriptions over the subsequent 12 months."

British Society of Gastroenterology Annual Meeting
20 March 2001

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us